We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 196

Eli Lilly Canada Inc. et al. v. Novopharm Limited

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 15 2010

Lilly commenced an action for patent infringement, and Novopharm, by way of counterclaim, brought an action for damages pursuant to s 8 of the Patented Medicines (Notice of Compliance) Regulations

Canada (Minister of Health) v. Merck Frosst Canada Ltd

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 15 2010

An English translation of a decision relating to two appeals issued in May 2009 was issued by the Court

Apotex Inc. v. Merck Frosst Canada & Co.

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 15 2010

This is an action decided under s 8 of the Patented Medicines (Notice of Compliance) Regulations between Apotex and Merck relating to norfloxacin

Sanofi-aventis Canada Inc. et al. v. Novopharm Limited

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 15 2010

Following an infringement trial, where the patent was found to be invalid, Novopharm’s counterclaim under s 8 of the Patented Medicines (Notice of Compliance) Regulations is going forward

Apotex Inc. v. sanofi-aventis

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 15 2010

Apotex commenced an impeachment action against sanofi-aventis

Other industry happenings of note

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 15 2010

Health Canada published a Guidance for Sponsors: Information and Submission Requirements for Subsequent Entry Biologics (SEBs) and updated the Guidance Documents for Data Protection and the PMNOC Regulations

sanofi v. Pharmascience

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • May 25 2010

This is an assessment of costs following the discontinuance of a proceeding under the Patented Medicines (Notice of Compliance) Regulations

Eli Lilly Canada v Novopharm

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • June 2 2010

For the purposes of an appeal being heard shortly, Lilly filed a compendium containing the documents referred to in its Memorandum of Fact and Law, as well as 13 additional volumes containing documents from the appeal book and an additional Book of Authorities

Eli Lilly Canada v. Novopharm Limited

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • August 4 2010

The Court of Appeal overturned the decision of the trial judge which held that the patent was invalid

Other cases of interest

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 12 2010

Hospira brought this application for judicial review of the Minister’s decision rejecting a New Drug Submission (“NDS”) on the grounds that it did not comply with the Food and Drug Regulations (“Regulations”